Osama Hamdy, MD, PhD, and other researchers at Joslin Diabetes Center showed that patients with obesity and diabetes who lost at least 7% of their weight the first year stood a better chance of keeping it off.
Losing weight boosts health in many ways, bringing improvements in cardiovascular (CV) risk factors. Unfortunately, not everyone who loses weight keeps it off. What’s been unclear until now, however, is whether those initial benefits of weight loss linger even if some is regained.
A 5-year study led by Osama Hamdy, MD, PhD, director of the Obesity Clincial Program at Joslin Diabetes Center, sought answers for those questions, as well as a more basic one: can an intense intervention in a clinical setting keep the weight off for the long haul?
Researchers found that it can, but patients’ chances improve if they manage to lose at least 7% of their body weight in the first year. The study also found that gains in glycated hemoglobin (A1C) and triglycerides made with weight loss are the first to erode if weight is regained, while other improvements in lipid levels are sustained.
Hamdy presented the findings Saturday at the 75th Scientific Sessions of the American Diabetes Association in Boston. The study, “The Long-term Effects of Intensive Lifestyle Intervention on Cardiovascular Risk in Patients with Diabetes in a Real-World Clinical Setting: a 5-Year Longitudinal Study,” is the winner of this year’s Michaela Modan Memorial Award.
“When it comes to weight loss, we know that some people maintain it for a longer duration and some people regain that weight back,” Hamdy said. “It is unclear to us what the impact of sustained weight loss versus weight regain is on cardiovascular risk factors.”
The findings come from the work at Joslin’s “Why WAIT” initiative, which stands for Weight Achievement and Intensive Treatment, a 12-week program for persons with type 1 or type 2 diabetes mellitus. ‘Why WAIT” features a structured diet with meal replacements, adjustments to diabetes medications to promote weight loss, education sessions, and an exercise program.
On Saturday, Hamdy emphasized the importance of the exercise program, which increases from 20 to 30 minutes up to 4 times per week to 45 to 60 minutes per day 6 times per week. Strength training is a key element, as Hamdy said patients who stuck with this component had greater success in keeping weight off.
Researchers at Joslin selected 129 patients with diabetes and obesity who had been enrolled in “Why WAIT” for 1 year and divided them into 2 groups, based on their weight loss: Group A, which included 47.3% of the participants, had filed to maintain weight loss of 7%, and Group B (52.7%) had maintained 7% weight loss.
All participants lost an average of 23.8 pounds and maintained an average weight loss of 16.2 pounds at the 5-year mark. Group A maintained a weight loss of 8.4 pounds, compared with 23.1 pounds for Group B after 5 years.
Group A’s A1C levels decreased from 7.5 ± 1.3% to 6.7 ± 0.9% at 12 weeks, but at the 1-year mark A1C had increased to 7.7 ± 1.4%, and at 5 years it had increased further, to 8 ± 1.9% after group members regained some measure of weight.
Group B’s A1C levels decreased from 7.4 ± 1.2% to 6.4 ± 0.9% at 12 weeks and increased to 6.8 ± 1.2% at 1 year and 7.3 ± 1.5% at 5 years as they maintained their weight loss.
“Despite weight regain, Group A maintained significant improvement in (low-density lipoprotein) and (high-density lipoprotein) cholesterol, no change in blood pressure, but had worsening of serum triglycerides,” the researchers wrote in their abstract. Group B maintained a similar lipid profile for 5 years and the same blood pressure for the first 18 months.
Reference
Hamdy O, Mottalib A, Morsi A, et al. The long-term effects of intensive lifestyle intervention on cardiovascular risk in patients with diabetes in a real-world clinical setting: a 5-year longitudinal study. Diabetes. 2015; 64(suppl1) abstract 58-OR.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More